A pathway-dependency framework for acquired resistance to targeted therapy in EGFR-mutant, KRAS G12C-mutant, and BRAF V600E-mutant NSCLC.

doi:10.1016/j.phrs.2026.108367

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

A pathway-dependency framework for acquired resistance to targeted therapy in EGFR-mutant, KRAS G12C-mutant, and BRAF V600E-mutant NSCLC.

Pharmacological research - 1 Sept 2026

Li Xiaoxiao, Guo Yadong, Yang Shize

Abstract excerpt

Targeted therapies have improved outcomes in EGFR-, KRAS G12C-, and BRAF V600E-driven non-small cell lung cancer (NSCLC), but acquired resistance is molecularly and spatially heterogeneous. Driver-specific algorithms and validated biomarkers underpin post-progression care. Determining pathway activity, causal dependency, and a tractable therapeutic vulnerability requires evidence beyond detecting an acquired...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung
Share to Drug Resistance, Neoplasm
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Molecular Targeted Therapy

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed

Identifiers

PMID: 42562082
DOI: 10.1016/j.phrs.2026.108367

Genes

BRAF
EGFR
KRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.